, a publication of the Pulmonary Hypertension Association (PHA), is the trusted source of up-to-date news, community events listings and lifesaving information about pulmonary hypertension for patients, families and caregivers, healthcare professionals and supporters.

PHA on the Road – Milwaukee: Topics of Interest for All Participants

2018-09-14T20:47:57+00:00 September 14th, 2018|

The Pulmonary Hypertension Association (PHA) will host PHA on the Road: PH Patients and Families Education Forum in Milwaukee Saturday, Oct. 27. PHA on the Road is a unique education and networking event that provides structured sessions for patients, their families and caregivers to learn more about pulmonary hypertension (PH) and have questions answered by local PH

Georgia Fun Walk Celebrates 15th Year on October 13

2018-09-14T21:38:38+00:00 September 14th, 2018|

The Georgia Fun Walk, launched by Sally Maddox, Ed.D., Pulmonary Hypertension Association (PHA) Board of Trustees secretary, celebrates its 15th walk October 13. This year’s milestone walk promises to be a special day for people living with pulmonary hypertension (PH), their families, caregivers, sponsors and health care providers in the greater Atlanta area. The

Sickle Cell Disease and PH are No Match for Kentucky Volunteer Nicole Creech

2018-09-14T20:42:15+00:00 September 14th, 2018|

September is Sickle Cell Disease Awareness Month. Sickle cell disease (SCD) is a blood disorder that affects approximately 100,000 Americans, of whom 6-11 percent may develop pulmonary hypertension (PH). The Pulmonary Hypertension Association (PHA) is recognizing SCD Awareness Month by highlighting a prominent PHA volunteer living with SCD-associated PH. Imagine a six-month-old screaming in

Availability of Implantable System for Remodulin Likely Late 2019

2018-09-14T20:49:14+00:00 September 14th, 2018|

The Food and Drug Administration (FDA) recently approved the Implantable System for Remodulin® (ISR), a collaboration between United Therapeutics Corporation and Medtronic. The ISR is approved for adults with functional class I, II and III pulmonary arterial hypertension (PAH) who are receiving intravenous (IV) treprostinil therapy. There are a very limited number of ISRs currently

Make the Most of Your Health Insurance: Prepare Now for Open Enrollment

2018-09-14T20:40:03+00:00 September 14th, 2018|

Most types of health insurance limit when participants may enroll or make changes to their coverage. During most of the year, changes and additions are restricted to major life events such as losing a job, getting married or having a child. Open enrollment, or annual enrollment, is a period of time each year when

Tampa Bay PHA Support Group Shares Experience Weathering Hurricane Irma

2018-09-14T20:46:18+00:00 September 14th, 2018|

As the 2018 hurricane season begins, the PHA community reflects on the anniversary of last year’s terrible storms with an empowering tale of community, resourcefulness and courage. By Jodi Hamel and Carolyn Sheehy (aka. Peas and Carrots) Tampa Bay PHA support group leaders As we write this, it is exactly one year to the

Navigating Access to Generic Therapy

2018-09-14T20:44:07+00:00 September 14th, 2018|

The Pulmonary Hypertension Association (PHA) reported Aug. 17 that generic tadalafil was approved by the Food and Drug Administration (FDA) and suggested that pulmonary hypertension (PH) patients taking Adcirca® discuss the implications with their care teams. Since then, generic tadalafil has become available through many health insurance plans. In addition, PHA has been advised

PHA on the Road – Long Beach: Speaker Highlights

2018-09-14T20:51:03+00:00 September 14th, 2018|

The Pulmonary Hypertension Association (PHA) will host PHA on the Road: PH Patients and Families Education Forum Saturday, Sept. 29, in Long Beach, Calif. This unique education and networking forum provides people living with pulmonary hypertension (PH), their families, caregivers and friends with a unique opportunity to learn from local PH experts alongside others in

Treating PH: Joint Symposium Discusses Options

2018-09-07T20:04:55+00:00 September 7th, 2018|

by Phyllis Hanlon, Contributing Writer Although there are 14 different Food and Drug Administration (FDA)-approved therapies for treating World Health Organization (WHO) Group 1 pulmonary hypertension (PH) (pulmonary arterial hypertension, or PAH), there remains a need for treatments that can be used across varying classifications of PH. In 2017, the Critical Care Medicine Department of

Share Your Oxygen Experiences: PHA Responds to Proposed Changes to Medicare Oxygen Coverage

2018-09-07T20:07:48+00:00 September 7th, 2018|

The Centers for Medicare and Medicaid Services (CMS) has proposed significant changes to how home oxygen (also known as supplemental oxygen) is regulated and paid for. The Pulmonary Hypertension Association (PHA) is taking action to improve the pulmonary hypertension (PH) community’s experience accessing home oxygen. If you have been prescribed home oxygen, you can help